Infusion of allogeneic anti-CD19 CAR T-cells is a promising approach after alloHSCT - European Medical Journal

Infusion of allogeneic anti-CD19 CAR T-cells is a promising approach after alloHSCT

Hematology

Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides an overview of a trial of allogeneic T-cells that were genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>